CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher

CONy16: New Alzheimer’s Phase 3 Tests of Amyloid-Beta Immunotherapies and an Exclusive Interview with Researcher
Two previously failed drug candidates, Eli Lilly’s Solanezumab and Roche’s Gantenerumab, are again under clinical study for Alzheimer’s disease. Both drugs are immunotherapies targeting amyloid-beta in the brain, a target that researchers — including Dr. Michael Geschwind, who spoke with Alzheimer’s News Today — think has the potential to revolutionize Alzheimer’s treatment. Amyloid-beta has long been the focus of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *